Viewing nowCombinationPosigledio Extended Release Tablet 10/500 mg
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.

MFDS item code 202301855 · Approved 2023.06.16 · Insurance code 653806270
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication helps improve blood sugar control in adults with type 2 diabetes by combining dapagliflozin and metformin. It is used as an adjunct to diet and exercise in patients whose blood sugar is not well controlled, and is particularly effective when blood sugar levels are insufficiently regulated. Additionally, consideration should be given to its impact on cardiovascular events for patients with existing cardiovascular disease or risk factors, so consulting a specialist is essential. This medication enhances blood sugar control and assists in managing type 2 diabetes.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be titrated gradually to reduce gastrointestinal adverse reactions caused by metformin. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose may be started at the existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because any change may cause alterations in blood glucose control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling the tablet. Renal impairment No dosage adjustment is required in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the eGFR decreases to less than 45 mL/min/1.73m2, treatment with this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is more likely to be reduced in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
This medication helps control blood sugar levels. However, it can rarely cause a serious condition known as lactic acidosis; hence, it should not be used in patients with poor kidney function or severe infections or dehydration. Additionally, caution is needed when used with insulin or other diabetes medications, as there is a risk of hypoglycemia. It should not be administered to patients with moderate to severe renal impairment, liver dysfunction, or to women who are pregnant or breastfeeding. This medication should be temporarily discontinued before surgery or examinations using iodine contrast agents, and resumed only after kidney function has been confirmed as normal. Use in elderly patients or those with reduced fluid volume or at risk of low blood pressure should be done cautiously, with periodic monitoring of blood pressure and kidney function. During treatment with this medication, genital infections or urinary tract infections may occur, and should be promptly treated upon symptom onset. Additionally, vitamin B12 deficiency may occur, so routine blood tests are recommended to monitor levels. Excessive alcohol consumption can increase the risk of side effects of this medication, so it should be avoided. This medication is contraindicated during pregnancy, and should be discontinued immediately upon confirmation of pregnancy. The use in children or elderly patients over 80 years is not recommended, and kidney function must be checked in elderly patients. In case of overdose, it is imperative to seek medical attention immediately. Lastly, this medication should be kept out of reach of children and stored in its original container.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain storage temperature between 1 and 30 degrees Celsius.
Pink, double-sided convex oval shaped extended-release film-coated tablet
30 tablets/box [(6 tablets/PTP)*5], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daewoo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Il-Yang Pharmaceutical Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
CombinationDapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
Dapagliflozin Anhydrous Lactose Mixture 15.27mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Albogen Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.